Skip to main content

Table 2 Clinical and laboratory parameters in LC group and non-LC group

From: The incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription: a retrospective study in South Korea (1999–2014)

Clinical and laboratory parametersLC group (n = 19)Non-LC group (n = 3)P
Age57.4 ± 9.963.0 ± 7.60.361
Sex  0.273
 Male (%)11 (57.9)3 (100) 
 Female (%)8 (42.1)0 (0) 
Drug duration (days)13.2 ± 8.618.7 ± 10.50.328
Drug total dose (mg)3831.6 ± 2513.85600.0 ± 3152.20.284
WBC (× 103/uL)6.2 ± 3.412.0 ± 1.60.009
CK (U/L)21,132.1 ± 16,865.720,930.0 ± 9363.70.984
LDH (U/L)2416.1 ± 1578.61716.0 ± 753.20.466
AST (U/L)1088.3 ± 638.21403.5 ± 748.80.518
ALT (U/L)374.5 ± 244.2467.5 ± 105.40.606
Albumin (g/dL)2.7 ± 0.53.5 ± 0.80.034
BUN (mg/dL)26.5 ± 22.950.6 ± 40.90.141
Creatinine (mg/dL)1.6 ± 1.83.9 ± 3.50.075
Sodium (mmol/L)134.9 ± 6.5140.3 ± 4.70.186
Potassium (mmol/L)4.5 ± 0.74.9 ± 0.70.336
Hospital days24.0 ± 9.511.0 ± 5.60.081
Clinical signs and symptoms
 Muscle pain (%)17 (89.5)3 (100)1.000
 Muscle weakness (%)8 (42.1)1 (33.3)1.000
 Oliguria (%)2 (10.5)2 (66.7)0.371
Dark urine (%)2 (10.5)1 (33.3)0.073
DM (%)1 (5.2)01.000
ARF (%)5 (26.3)2 (66.7)0.227
Death (%)4 (21.1)0 (0)0.603
Child-Pugh classification
 A (%)3 (15.8)NA 
 B (%)7 (36.8)NA 
 C (%)9 (47.4)NA 
Etiology of LC NA 
 Hepatitis B (%)12 (63.2)NA 
 Hepatitis C (%)2 (10.5)NA 
 Alcohol (%)4 (21.1)NA 
 Cryptogenic (%)1 (5.2)NA 
  1. WBC White Blood Cell, CK Creatine Kinase, LDH Lactate Dehydrogenase, AST Aspartate Transaminase, ALT Alaninine Transminase, BUN Blood Urea Nitrogen, DM Diabetes Mellitus, ARF Acute Renal Failure, LC Liver Cirrhosis